Overview

AZD3241 PET MSA Trial, Phase 2, Randomized,12 Week Safety and Tolerability Trial With PET in MSA Patients

Status:
Completed

Trial end date:
2016-09-19

Target enrollment:

Participant gender:

Summary

AZD3241 myeloperoxidase (MPO) inhibitor trial is assessing safety and tolerability, randomized trial, in patients with Multiple System Atrophy.

Phase:

Phase 2

Details

Lead Sponsor:

AstraZeneca